FDA Plans to Get Tough On Clinical Trials That Don’t Include Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WASHINGTON-The FDA has proposed a new regulation that would make sure pharmaceutical companies comply with a 1993 order to include women in all phases of drug testing. An examination of some 4,000 trials done in the last three years showed that approximately one quarter still excluded women of childbearing age solely because they could become pregnant during the trial.

WASHINGTON—The FDA has proposed a new regulation that would make sure pharmaceutical companies comply with a 1993 order to include women in all phases of drug testing. An examination of some 4,000 trials done in the last three years showed that approximately one quarter still excluded women of childbearing age solely because they could become pregnant during the trial.

The new rule would allow the FDA to stop or prevent clinical trials of agents for use in serious or life-threatening conditions if they exclude women of childbearing age. The rule would apply even to drugs suspected of causing birth defects. The FDA will decide whether to finalize the measure after a 90-day period for public comment.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Related Content